ABSTRACT
Identifying COVID-19 outbreaks in hospitals at an early stage requires active surveillance. Our objective was to assess whether floor swabs correlated with COVID-19 outbreak status in hospital. We swabbed the floors of an inpatient ward at Mount Sinai Hospital for 32 weeks, from October 31, 2022 to June 15, 2023 and RT-qPCR analysis provided a quantification cycle of detection for each positive swab. 182 swabs were processed for SARS CoV-2, of which 98.4% were positive. Two COVID-19 outbreaks were declared during the study period. The median viral copy number was 210 (IQR, 49 to 1018) during non-outbreak periods and 653 (IQR, 300 to 1754) during outbreak periods. Analyzing the number of viral copies of SARS-CoV-2, instead of percentage positivity, gave a clearer view of changes in outbreak status over time, thereby illustrating the benefits of this approach to monitor pathogen load in hospital settings.
Competing Interest Statement
Dr. Michael Fralick is an advisor to Signal1, a start-up company that implements machine-learned solutions into clinical practice; in addition, he was a consultant for ProofDx, a start-up company that created a point-of-care device for COVID-19 using CRISPR.
Funding Statement
This project was supported by a CIHR Operating Grant (EGA 179419) and the Sinai Health Department of Medicine Research Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Study concept and design: All authors
Acquisition of data: All authors
Analysis/interpretation of data: All authors
Drafting of the manuscript: Ray P, Fralick M
Critical revision of the manuscript: All authors
Statistical analysis: All authors
Funding Statement: This project was supported by a CIHR Operating Grant (EGA 179419) and the Sinai Health Department of Medicine Research Fund.
Conflicts of Interest: MF is an advisor to Signal1, a start-up company that implements machine-learned solutions into clinical practice; in addition, he was a consultant for ProofDx, a start-up company that created a point-of-care device for COVID-19 using CRISPR.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
